Next Article in Journal
Anterior Scleral Regional Variation between Asian and Caucasian Populations
Next Article in Special Issue
The New ELN Recommendations for Treating CML
Previous Article in Journal
Revision Arthroscopic Bankart Repair: A Systematic Review of Clinical Outcomes
Previous Article in Special Issue
Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
Article

Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors

1
Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva 49100, Israel
2
Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
3
Israeli CML Patients Organization, 5 Ehud Manor st., Netanya 4265952, Israel
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(11), 3417; https://doi.org/10.3390/jcm9113417
Received: 28 September 2020 / Revised: 20 October 2020 / Accepted: 21 October 2020 / Published: 25 October 2020
(This article belongs to the Special Issue Prognosis and Therapy of Chronic Myeloid Leukemia)
The life expectancy of patients with chronic myeloid leukemia (CML) approaches that of the age-matched population and quality of life (QOL) issues are becoming increasingly important. To describe patients’ characteristics and assess QOL, we delivered a 30-item core questionnaire, a 24-item CML-specific questionnaire, both from the European Organization for Research and Treatment of Cancer (EORTC), and additional health-related items to 350 patients. Among 193 patients who completed the questionnaires, 139 received either imatinib (n = 70, 33%), dasatinib (n = 45, 23%) or nilotinib (n = 24, 12%). Patients’ median age was 58 (range: 23 to 89) years and 86 (63%) were males. Stratifying patients by treatment, we recognized two distinct populations. In comparison to patients on dasatinib and nilotinib, patients on imatinib were two decades older, had a longer duration of disease and current treatment, experienced fewer limitations on daily activities (p = 0.02), less fatigue (p = 0.001), lower degree of impaired body image (p = 0.022) and less painful episodes (p = 0.014). Similarly, they had better emotional functioning, were less worried, stressed, depressed or nervous (p = 0.01) and were more satisfied with their treatment (p = 0.018). Not only does age associate with current treatments, but it also predicts how patients perceive QOL. Young patients express impaired QOL compared with elderly patients. View Full-Text
Keywords: quality of life; chronic myeloid leukemia; tyrosine kinase inhibitors; patient-reported outcome quality of life; chronic myeloid leukemia; tyrosine kinase inhibitors; patient-reported outcome
Show Figures

Figure 1

MDPI and ACS Style

Shacham Abulafia, A.; Shemesh, S.; Rosenmann, L.; Berger, T.; Leader, A.; Sharf, G.; Raanani, P.; Rozovski, U. Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors. J. Clin. Med. 2020, 9, 3417. https://doi.org/10.3390/jcm9113417

AMA Style

Shacham Abulafia A, Shemesh S, Rosenmann L, Berger T, Leader A, Sharf G, Raanani P, Rozovski U. Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors. Journal of Clinical Medicine. 2020; 9(11):3417. https://doi.org/10.3390/jcm9113417

Chicago/Turabian Style

Shacham Abulafia, Adi, Sivan Shemesh, Lena Rosenmann, Tamar Berger, Avi Leader, Giora Sharf, Pia Raanani, and Uri Rozovski. 2020. "Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors" Journal of Clinical Medicine 9, no. 11: 3417. https://doi.org/10.3390/jcm9113417

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop